Optimizing treatment in recurrent epithelial ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006;98:1655–1663.
   PubMed Web of Science ®Google Scholar
• Stuart GC, Kitchener H, Bacon M, et al. Gynecologic Cancer Intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2010;21(4):750–755. 2011
   Web of Science ®Google Scholar
• Harter P, Hilpertm F, Mahner S, et al. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10(1):81–88.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(4):771–775.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Van Der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–1163.
   PubMed Web of Science ®Google Scholar
• Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer Intergroup: recurrent disease. Ann Oncol. 2017;28(4):727–732.
   PubMed Web of Science ®Google Scholar
• Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60(2):159–179.
   PubMed Web of Science ®Google Scholar
• International Collaboration for Ovarian Neoplasia Group. Paclitaxel plus platinum based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106.
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323–3329.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly (adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844–1852.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Penson RT, et al. Colombo treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecol Oncol. 2017;145(S1):219–220.
   PubMedGoogle Scholar
• Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39–48.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Raspagliesi F, et al. The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: a collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. J Clin Oncol. 2016;34(S15):5505–5505.
   Google Scholar
• Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195–208.
   PubMedGoogle Scholar
• Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436–440.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open label randomized phase III trial. J Clin Oncol. 2014;32:1302–1308.
   PubMed Web of Science ®Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32:1309–1316.
   PubMed Web of Science ®Google Scholar
• Poveda AM, Selle F, Hilpert F, et al. Weekly paclitaxel, pegylated liposomal doxorubicin or topotecan ± bevacizumab in platinum-resistant ovarian cancer: analysis by chemotherapy cohort in the GCIG AURELIA randomised phase III trial [abstract LBA26]. Ann Oncol. 2012;23(S9):ix7–608.
   PubMedGoogle Scholar
• Harter P, Du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–1710.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.J. Clin Oncol 35. 2017. (15 suppl; abstr 5501).
   Google Scholar
• Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127:502–505.
   PubMed Web of Science ®Google Scholar
• Petrillo M, De Iaco P, Cianci S, et al. Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1660–1665.
   PubMed Web of Science ®Google Scholar
• Hotouras A, Desai D, Bhan C, et al. Heated intraperitoneal chemotherapy (hipec) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer. 2016;26:661–670.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and hipec in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–1575.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–428.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol. 2012;23(Suppl. 10):128–131.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.Gynecol. Oncol. 2010;119(1):32–37.
   Google Scholar
• Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–1074.
   PubMed Web of Science ®Google Scholar
• Huang J, Bae JO, Tsai JP, et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol. 2009;34:79–87.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(8):799–808.
   PubMed Web of Science ®Google Scholar
• Marth C, Vergote I, Scambia G, et al. ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017;70:111–121.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N Engl J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;137(3):386–391.
   PubMed Web of Science ®Google Scholar
• Reiss KA, Herman JM, Armstrong D, et al. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol. 2017;144(3):486–490.
   PubMed Web of Science ®Google Scholar
• De Bono J, Ramanathan RK, Mina L, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620–629.
   PubMed Web of Science ®Google Scholar
• Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet TIG. 2013;29(7):394–402.
   PubMed Web of Science ®Google Scholar
• Leijen S, Van Geel R, Sonke GS, et al. Phase II study with wee1 inhibitor AZD1775 (MK-1775) plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy. J Clin Oncol. 2015;33(15s):2507.
   Google Scholar
• Armstrong DK, White AJ, Weil SC, et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129(3):452–458.
   PubMed Web of Science ®Google Scholar
• Walters CL, Arend RC, Armstrong DK, et al. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 2013;131(2):493–498.
   PubMed Web of Science ®Google Scholar
• Kathleen NM, Lainie PM, David MO, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase i expansion study. J Clin Oncol. 2017;35(10):1112–1118.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022.
   PubMed Web of Science ®Google Scholar
• Varga A, Piha-Paul SA, Ott PA, et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028. J Clin Oncol 2017;35. (15 suppl; abstr 5513).
   PubMedGoogle Scholar
• NCT01611558 Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer – study results. https://clinicaltrials.gov/ct2/show/results/NCT01611558. Accessed 2016 May 24
   Google Scholar
• Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. J Clin Oncol. 2015;33(15s):5509.
   Google Scholar
• Infante JR, Braiteh F, Emens LA, et al. Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Ann Oncol. 2016;27(6):296–312.
   Google Scholar
• Tolaney S, Birrer M, Fleming G, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49:2972–2978.
   PubMed Web of Science ®Google Scholar
• McAlpine JN, Porter H, Köbel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740–750.
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1 of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587–13598.
   PubMed Web of Science ®Google Scholar